Izotropic Corp.

Izotropic Corp.

0.16
CAD
+0.01
(+3.23%)
-0.04EPS
21.96MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.03
-0.02
-0.05
-0.14
-0.15
-0.11
-0.03
-0.05
-0.03
-0.04
Free Cash Flow per Basic Share
- -
-0.03
-0.02
-0.04
-0.09
-0.11
-0.07
-0.01
-0.01
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.02
0.01
0.02
0.11
-0.01
-0.06
-0.07
-0.08
-0.08
-0.08
Tangible Book Value per Share
- -
0.02
0.01
0.02
0.11
-0.01
-0.06
-0.07
-0.08
-0.08
-0.08
Basic Weighted Avg Shares
22
22
23
25
35
43
50
54
59
67
66
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
- -
-1
-5
-7
-6
-2
-3
-2
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
1
5
- -
-3
-4
-5
-6
-6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
1
5
- -
-3
-4
-5
-6
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-110
-225.74
-190.49
- -
- -
- -
- -
- -
- -

Capital Structure

CAD

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
67
68
70
Market Capitalization
30
17
22

Working Capital

CAD

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
Total Current Assets
- -
1
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
6
6
Payables & Accruals
3
3
3
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
135.9%
15.76%
Free Cash Flow
- -
-3.35%
33.56%
Net Income, GAAP
- -
3.41%
-30.42%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
- -
-0.03
2025
-0.02
-0.01
-0.01
-0.02
-0.05
2026
- -
-0.01
- -
-0.01
-0.03

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Robert Louis Thast
Full Time Employees
5
Sector
Health technology
Industry
Medical specialties
Address
800 – 15355 24th Avenue Surrey BC Canada V4A 2H9
IPO Date
May 31, 2018
Business
Izotropic Corporation is a MedTech enterprise specializing in advanced diagnostic imaging for the early detection and characterization of breast cancers. The company is actively commercializing its flagship product, the IzoView Breast CT Imaging System, a dedicated 3D platform that delivers high-resolution volumetric imaging without breast compression. This innovative system integrates artificial intelligence for image reconstruction and offers a patent-pending personalized radiation dose, particularly addressing the challenges in detecting cancer in women with dense breast tissue. The corporation was formed in 2016 and is headquartered in Surrey, Canada.

Company News

  • Izotropic Closes Non-Brokered Private Placement

  • Izotropic Announces Non-Brokered Private Placement

  • Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC

  • Izotropic Africa Launches Operations in Casablanca

  • Izotropic Announces Debt Settlement

  • Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health

  • Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC

  • Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement

  • Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement

  • Izotropic (OTCMKTS:IZOZF) Sets New 1-Year High – Here’s What Happened

  • Izotropic Announces AGM Results

  • Izotropic (OTCMKTS:IZOZF) Shares Up 4.2% – What’s Next?

  • Izotropic Launches Podcast Episode #2: AI and the Future of Breast Imaging: How Izotropic is Leading the Innovation

  • Izotropic Launches "Breast Imaging News" Page on BreastCT.com

  • NetworkNewsAudio Announces Audio Press Release (APR) on Breast CT Imaging System Capitalizing on Proprietary AI Tech

  • Izotropic Corporation's (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System

  • Izotropic CEO Interview: IzoView Differentiators, Regulatory Plans, and Outlook

  • Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) Stands Out with Proprietary Next-Gen Breast CT Imaging System

  • CEO.CA's Inside the Boardroom: This Breast Cancer Tech by Izotropic Targets 50% of Women Currently Underserved

  • Izotropic Marks Breast Cancer Awareness Month by Highlighting Gaps in Care and the Need for IzoView Breast CT